Response to "evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity"

B C Carleton; C J Ross; A P Bhavsar; J W Lee; H Visscher; S R Rassekh; M R Hayden

doi:10.1038/clpt.2014.90

Response to "evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity"

Clin Pharmacol Ther. 2014 Aug;96(2):158. doi: 10.1038/clpt.2014.90. Epub 2014 Apr 22.

Authors

B C Carleton¹, C J Ross², A P Bhavsar³, J W Lee⁴, H Visscher⁵, S R Rassekh⁶, M R Hayden⁷

Affiliations

¹ 1] Child and Family Research Institute, Vancouver, British Columbia, Canada [2] Division of Translational Therapeutics, Department of Pediatrics, The University of British Columbia, Vancouver, British Columbia, Canada [3] Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, British Columbia, Canada.
² 1] Child and Family Research Institute, Vancouver, British Columbia, Canada [2] Division of Translational Therapeutics, Department of Pediatrics, The University of British Columbia, Vancouver, British Columbia, Canada [3] Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, British Columbia, Canada [4] Centre for Molecular Medicine and Therapeutics; Department of Medical Genetics, The University of British Columbia, Vancouver, British Columbia, Canada.
³ 1] Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, British Columbia, Canada [2] Centre for Molecular Medicine and Therapeutics; Department of Medical Genetics, The University of British Columbia, Vancouver, British Columbia, Canada.
⁴ 1] Child and Family Research Institute, Vancouver, British Columbia, Canada [2] Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, British Columbia, Canada [3] Centre for Molecular Medicine and Therapeutics; Department of Medical Genetics, The University of British Columbia, Vancouver, British Columbia, Canada.
⁵ Department of Pediatrics, Amalia Children's Hospital, Radboud University Medical Centre, Nijmegen, The Netherlands.
⁶ 1] Child and Family Research Institute, Vancouver, British Columbia, Canada [2] Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, British Columbia, Canada [3] Division of Pediatric Hematology/Oncology/Bone Marrow Transplant, Department of Pediatrics, BC Children's Hospital, Vancouver, British Columbia, Canada.
⁷ Centre for Molecular Medicine and Therapeutics; Department of Medical Genetics, The University of British Columbia, Vancouver, British Columbia, Canada.

PMID: 24755913
DOI: 10.1038/clpt.2014.90

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Animals
Antineoplastic Agents / toxicity*
Catechol O-Methyltransferase / genetics*
Cisplatin / toxicity*
Female
Hearing Loss / chemically induced*
Humans
Male
Methyltransferases / genetics*
Multidrug Resistance-Associated Proteins / genetics*

Substances

Antineoplastic Agents
Multidrug Resistance-Associated Proteins
Methyltransferases
Catechol O-Methyltransferase
Cisplatin

Grants and funding

Canadian Institutes of Health Research/Canada